- Home
- ATCX vs JSPR Comparison
ATCX vs JSPR Comparison
Compare ATCX & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ATCX | JSPR |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | Brazil | United States |
| Employees | 13 | 22 |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.8M | 23.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ATCX | JSPR |
|---|---|---|
| Price | $5.54 | $0.93 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 11 |
| Target Price | $13.75 | ★ $15.50 |
| AVG Volume (30 Days) | 37.6K | ★ 327.7K |
| Earning Date | 03-16-2023 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $827,667.00 | N/A |
| Revenue Next Year | $166.45 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.39 | $0.62 |
| 52 Week High | $14.01 | $7.19 |
Technical Indicators
Market Signals| Indicator | ATCX | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 49.90 | 46.90 |
| Support Level | $4.66 | $0.81 |
| Resistance Level | $5.62 | $1.12 |
| Average True Range (ATR) | 0.34 | 0.08 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 54.78 | 52.49 |
Price Performance
Historical ComparisonAbout ATCX Atlas Critical Minerals Corporation Common Stock
Atlas Critical Minerals Corp is a mineral exploration and development company focused on critical minerals projects and properties in Brazil. The company's portfolio principally includes mineral properties for rare earths, graphite, titanium, copper, uranium, and nickel. It also owns mineral rights for iron ore, quartzite, gold, and diamond properties. The company's project portfolio includes the Alto Paranaiba, Malacacheta, Arcos, Goias, Tocantins, Rio Piracicaba, and other projects.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.